These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 12759327)

  • 41. Is the relationship among outcome variables shown in randomized trials?
    Schriger DL; Cooper RJ; Lopez-O'Sullivan A; Wystrach C; Altman DG
    Trials; 2015 Feb; 16():57. PubMed ID: 25886370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes.
    Pogue J; Devereaux PJ; Thabane L; Yusuf S
    PLoS One; 2012; 7(4):e34785. PubMed ID: 22529934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Composite outcomes can distort the nature and magnitude of treatment benefits in clinical trials.
    Ferreira-Gonzalez I; Permanyer-Miralda G; Busse JW; Devereaux PJ; Guyatt GH; Alonso-Coello P; Montori VM
    Ann Intern Med; 2009 Apr; 150(8):566-7. PubMed ID: 19380859
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of relative and absolute effect measures in reporting health inequalities: structured review.
    King NB; Harper S; Young ME
    BMJ; 2012 Sep; 345():e5774. PubMed ID: 22945952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inadequate Reporting of Analytical Characteristics of Biomarkers Used in Clinical Research: A Threat to Interpretation and Replication of Study Findings.
    Sun Q; Welsh KJ; Bruns DE; Sacks DB; Zhao Z
    Clin Chem; 2019 Dec; 65(12):1554-1562. PubMed ID: 31672858
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is Mortality a Useful Primary End Point for Critical Care Trials?
    Veldhoen RA; Howes D; Maslove DM
    Chest; 2020 Jul; 158(1):206-211. PubMed ID: 31790654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Combined endpoints].
    Kleist P
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(3):239-42; discussion 243. PubMed ID: 20608253
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moderators of treatment outcomes: clinical, research, and policy importance.
    Kraemer HC; Frank E; Kupfer DJ
    JAMA; 2006 Sep; 296(10):1286-9. PubMed ID: 16968853
    [No Abstract]   [Full Text] [Related]  

  • 49. Statistical properties of Continuous Composite Outcomes: Implications for clinical trial design.
    Troy JD; Simmons RA
    Contemp Clin Trials Commun; 2020 Dec; 20():100655. PubMed ID: 33024883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Should we use composite outcomes in obstetric clinical prediction models?
    Giles-Clark HJ; Skinner SM; Rolnik DL; Mol BW
    Eur J Obstet Gynecol Reprod Biol; 2023 Jun; 285():193-197. PubMed ID: 37148646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Composite Outcomes in Clinical Prediction Modeling: Are We Trying to Predict Apples and Oranges?
    Dash K; Goodacre S; Sutton L
    Ann Emerg Med; 2022 Jul; 80(1):12-19. PubMed ID: 35339284
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving the health of patients and populations requires humility, uncertainty, and collaboration.
    Oxman AD
    JAMA; 2012 Oct; 308(16):1691-2. PubMed ID: 23093168
    [No Abstract]   [Full Text] [Related]  

  • 53. Mechanisms and uncertainty in randomized controlled trials: A commentary on Deaton and Cartwright.
    Suzuki E; VanderWeele TJ
    Soc Sci Med; 2018 Aug; 210():83-85. PubMed ID: 29703448
    [No Abstract]   [Full Text] [Related]  

  • 54. Composite outcomes for pain clinical trials: considerations for design and interpretation.
    Gewandter JS; McDermott MP; Evans S; Katz NP; Markman JD; Simon LS; Turk DC; Dworkin RH
    Pain; 2021 Jul; 162(7):1899-1905. PubMed ID: 33449513
    [No Abstract]   [Full Text] [Related]  

  • 55. Composite outcomes in randomized clinical trials: arguments for and against.
    Ross S
    Am J Obstet Gynecol; 2007 Feb; 196(2):119.e1-6. PubMed ID: 17306647
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Composite outcomes in clinical trials: uses and problems.
    Carneiro AV
    Rev Port Cardiol; 2003 Oct; 22(10):1253-63. PubMed ID: 14708338
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review.
    Cordoba G; Schwartz L; Woloshin S; Bae H; Gøtzsche PC
    BMJ; 2010 Aug; 341():c3920. PubMed ID: 20719825
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.
    Ferreira-González I; Busse JW; Heels-Ansdell D; Montori VM; Akl EA; Bryant DM; Alonso-Coello P; Alonso J; Worster A; Upadhye S; Jaeschke R; Schünemann HJ; Permanyer-Miralda G; Pacheco-Huergo V; Domingo-Salvany A; Wu P; Mills EJ; Guyatt GH
    BMJ; 2007 Apr; 334(7597):786. PubMed ID: 17403713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of composite end points to measure clinical events.
    van Leth F; Lange JM
    JAMA; 2003 Sep; 290(11):1456-7; author reply 1457. PubMed ID: 13129983
    [No Abstract]   [Full Text] [Related]  

  • 60. How effective is that treatment? The number needed to treat.
    Deahl ST
    Tex Dent J; 2011 Feb; 128(2):211-9. PubMed ID: 21473250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.